COMPANY PROFILE

GENECAST

Ultra-sensitive liquid biopsy technology for early cancer detection and monitoring, enhancing diagnosis and treatment outcomes

Seoul, South KoreaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About GENECAST

A biotechnology company specializing in cancer diagnosis through liquid biopsy, a non-invasive method that analyzes circulating tumor DNA (ctDNA) in the blood.

Its proprietary Allele-Discriminating Priming System (ADPS) technology serves as the core of its diagnostic services, enabling the detection of cancer with high sensitivity (0.0001%). This allows for early diagnosis and monitoring of treatment effectiveness through Minimal Residual Disease (MRD) testing.

The company's product portfolio includes tests like 'Genecast Focus', which targets 41 key driver genes in major solid tumors such as non-small cell lung cancer and colorectal cancer, and 'Genecast THEMIS' for ongoing screening.

GENECAST's business model revolves around providing these advanced diagnostic tools to healthcare providers and physicians to improve cancer survival rates and patient outcomes. The company operates in the precision medicine market, catering to the growing demand for personalized cancer treatment.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Seoul, South Korea
Employees: 16
Open positions: None listed
Dealroom signal: 63.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, DNA, Biomarkers, Genetics and genomics, Precision Medicine, Health Diagnostics, Spinout, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jun 2024	$4.6M	$108M	Undisclosed	↗
LATE VC✓Equity / VC	Feb 2023	$20M	$78M	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

GENECAST website traffic

Latest recorded traffic for GENECAST is 110 monthly website visits, down 42.1% over the last three months. GENECAST's team declined 11.1% over the past year.

Latest monthly visits110 3-month web change-42.1% 1-year team growth-11.1%

Monthly website visitsApr 2020–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBiofidelityRapid genomic biomarker detection for precision oncology	Cambridge, United Kingdom	Operational	29	$61M	$96M
ALAllelicaSoftware as a Service that allows clinical genetics lab to perform Polygenic Risk Score analysis	New York City, United States	Operational
OPOphiomicsOphiomics develops bioinformatics/genomics-based diagnostic products and services for liver cancer diagnosis, prognosis and follow-up.	Lisbon, Portugal	Operational
PIPierianDxEnables clinical labs to deliver patient-specific diagnosis and treatments	St. Louis, United States	Acquired
HLHuman LongevityA genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived	San Diego, United States	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
MIMicrobaMicrobial genomics company	Brisbane, Australia	Operational
KOKura OncologyA clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers	San Diego, United States	Operational